Guillemare E, Honore E, De Weille J, Fosset M, Lazdunski M, Meisheri K
Institut de Pharmacologie Moleculaire et Cellulaire, Centre Nationale de la Recherche Scientifique, Valbonne, France.
Mol Pharmacol. 1994 Jul;46(1):139-45.
Follicle-enclosed Xenopus oocytes were used to describe the ATP-sensitive K+ (KATP) channel-blocking properties of U-37883A (4-morpholinecarboximidine-N-1-adamantyl-N'-cyclohexyl), in comparison with glibenclamide. In follicular oocytes, the KATP channel opener P1060 (30 microM), a pinacidil analog, activated a large outward K+ current that was blocked by glibenclamide (IC50 = 0.33 microM) and U-37883A (IC50 = 0.26 microM). P1060 activation was inhibited by both U-37883A and glibenclamide in a noncompetitive manner. U-37883A also blocked the KATP channel activation by cAMP (300 microM) and adenosine (10 microM). Single-channel studies on isolated follicular cells showed that U-37883A (10 microM) reduced the open probability of the KATP channel by 76%, without significantly modifying the single-channel current amplitude. Receptor binding studies with [3H]U-37883 in membranes from follicle-enclosed oocytes demonstrated a single class of low affinity binding sites, with a Kd of 450 nM and a Bmax of 17 pmol/mg of protein. Studies with analogs of U-37883A showed that U-52090A inhibited KATP current and displaced [3H]U-37883 from its binding site with similar potencies. In contrast, U-42069D neither inhibited KATP current nor competed with [3H]U-37883 binding. In RINm5F cells (an insulinoma cell line), U-37883A, unlike glibenclamide, failed to inhibit KATP current. Furthermore, there was no significant specific binding of [3H]U-37883 in RINm5F cell membranes, which displayed high levels of specific binding of [3H]glibenclamide. These data demonstrate the presence of a receptor for U-37883A-type guanidines that controls the activity of the endogenous KATP channels in follicle-enclosed oocytes. The available data collectively suggest that U-37883A is a more selective blocker of the follicular KATP channel, which is very similar to that in smooth muscle, than of the pancreatic beta cell KATP channel.
将包裹在卵泡中的非洲爪蟾卵母细胞用于描述U - 37883A(4 - 吗啉甲脒 - N - 1 - 金刚烷基 - N' - 环己基)与格列本脲相比的ATP敏感性钾通道(KATP)阻断特性。在卵泡卵母细胞中,KATP通道开放剂P1060(30微摩尔),一种匹莫齐特类似物,激活了一个大的外向钾电流,该电流被格列本脲(IC50 = 0.33微摩尔)和U - 37883A(IC50 = 0.26微摩尔)阻断。P1060的激活被U - 37883A和格列本脲以非竞争性方式抑制。U - 37883A还阻断了cAMP(300微摩尔)和腺苷(10微摩尔)对KATP通道的激活。对分离的卵泡细胞进行的单通道研究表明,U - 37883A(10微摩尔)使KATP通道的开放概率降低了76%,而没有显著改变单通道电流幅度。用[3H]U - 37883对包裹在卵泡中的卵母细胞膜进行的受体结合研究表明存在一类低亲和力结合位点,Kd为450纳摩尔,Bmax为17皮摩尔/毫克蛋白质。对U - 37883A类似物的研究表明,U - 52090A抑制KATP电流并以相似的效力将[3H]U - 37883从其结合位点置换出来。相比之下,U - 42069D既不抑制KATP电流也不与[3H]U - 37883结合竞争。在RINm5F细胞(一种胰岛素瘤细胞系)中,U - 37883A与格列本脲不同,未能抑制KATP电流。此外,在RINm5F细胞膜中没有[3H]U - 37883的显著特异性结合,而该细胞膜显示出高水平的[3H]格列本脲特异性结合。这些数据证明存在一种U - 37883A类胍的受体,它控制包裹在卵泡中的卵母细胞内源性KATP通道的活性。现有数据共同表明,U - 37883A是卵泡KATP通道比胰腺β细胞KATP通道更具选择性的阻断剂,卵泡KATP通道与平滑肌中的非常相似。